https://www.selleckchem.com/pr....oducts/tiragolumab-a
74, P = .001). Grade ≥ 3 toxicity rate with RT was 30% and associated with mucosal subsite (OR 4.04, P = .03) and BMI 20 kg/m (OR 6.04, P = .012). Forty percent of patients (n = 59) were HIV-infected; most (85%) were on antiretroviral therapy, had suppressed viral loads (90% with ≤400 copies/mL), and had immunocompetent CD4 counts (median 400 cells/mm ). HIV-status was not associated with decreased receipt or delays of definitive RT, worse survival, or increased toxicity. Despite access to government-funded care, HNC
Like
Comment
Share
